Congress

Politics John Wilkerson

STAT Plus: Generics companies fought to stop the new drug pricing law. But they may end up benefiting

Politics Rachel Cohrs

STAT Plus: Medicare details forthcoming penalties for drug price hikes

Politics John Wilkerson

STAT Plus: Senate panel passes drug patent reforms, but not without dissent

Politics Rachel Cohrs

What people on Medicare can expect once the Covid-19 public health emergency ends

Politics Sarah Owermohle and John Wilkerson

STAT Plus: In State of the Union, Biden pitches addiction, mental health care policies as opportunities for bipartisanship

Biotech Rachel Cohrs

STAT Plus: How one biotech investor is changing his calculus now that Medicare can negotiate drug prices

Politics Rachel Cohrs

STAT Plus: Former Sen. Richard Burr to join health care practice at law and lobbying firm

Exclusive John Wilkerson

STAT Plus: Senators probe telehealth companies for tracking and monetizing sensitive health data

Politics Sarah Owermohle

STAT Plus: From industry ‘greed’ to workforce shortages, Sanders and Cassidy lay out health committee agenda

Politics Rachel Cohrs

STAT Plus: New York’s hospitals are poised for political power this Congress

Pharmalot Ed Silverman

STAT Plus: Warren urges the FTC to scrutinize two pharma mergers over “anti-competitive” practices

Politics Nicholas Florko

STAT Plus: After nearly 4 years of deliberation, FDA punts on how to regulate CBD

Politics John Wilkerson

STAT Plus: The 4 biggest questions about the FDA’s forthcoming changes to accelerated approvals

Politics Jonathan Wosen

STAT Plus: Liquid-biopsy firm Grail is spending more than ever lobbying Congress

Politics Sarah Owermohle

STAT Plus: Health groups like AHA, PhRMA channeled millions into end-of-year legislative debates

First Opinion Paul J. Hastings

STAT Plus: Biopharma leaders helped save democracy. Now what?

Politics John Wilkerson

STAT Plus: Congressional Medicare advisers warn of higher drug prices, despite new price negotiation

Politics Sarah Owermohle

Biden Covid adviser David Kessler to exit as pandemic response winds down

Politics Rachel Cohrs

STAT Plus: HHS will seek more input on its new Medicare drug price negotiations

Politics Rachel Cohrs

Will America’s public health reckoning ever come?

Hospitals Rachel Cohrs

STAT Plus: HHS will decide how to resolve $1 billion in payments for 340B hospitals

Politics Sarah Owermohle

Still fuming over the federal Covid response, Republicans redirect the House coronavirus committee

Politics Sarah Owermohle

STAT Plus: Rep. Jason Smith and the other Republicans leading health policy in the House

Health Nicholas Florko

Officials in Nebraska, South Dakota, Oklahoma begin to probe prisons’ hepatitis C treatment efforts

Politics Rachel Cohrs

STAT Plus: 3 drug pricing issues to watch in 2023

Business Bob Herman and Tara Bannow

STAT Plus: 3 trends to watch in hospitals and health insurance in 2023

The Aduhelm Files Rachel Cohrs, Adam Feuerstein and Damian Garde

STAT Plus: FDA, Biogen, and an Alzheimer’s drug approval: 8 key takeaways from congressional investigation

The Aduhelm Files Rachel Cohrs

STAT Plus: ‘Rife with irregularities’: Congressional investigation reveals FDA’s approval of Aduhelm marked by secret discussions, breaches of protocol

The Aduhelm Files Damian Garde and Adam Feuerstein

STAT Plus: Seeking maximum profits, Biogen set an ‘unjustifiably high price’ for Alzheimer’s treatment, investigation finds